ziprasidone has been researched along with Weight Loss in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ | 1 |
| Grignon, S; Roy-Desruisseaux, J | 1 |
| Chandler, RA; Childers, ME; Hill, SJ; Ketter, TA; Rasgon, NL; Wang, PW | 1 |
| Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
| Murray, S; Olié, JP; Spina, E; Yang, R | 1 |
| Loebel, A; Siu, C; Warrington, L; Yang, R; Zimbroff, D | 1 |
4 trial(s) available for ziprasidone and Weight Loss
| Article | Year |
|---|---|
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss | 2014 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Hospitalization; Humans; Ketones; Male; Middle Aged; Movement Disorders; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome; Weight Gain; Weight Loss | 2006 |
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Electrocardiography; Fasting; Humans; Lipids; Nausea; Piperazines; Prolactin; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Weight Loss | 2007 |
2 other study(ies) available for ziprasidone and Weight Loss
| Article | Year |
|---|---|
Protracted, dose-dependent weight loss after addition of ziprasidone to a stable regimen of clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Time Factors; Weight Loss | 2010 |
Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Body Mass Index; Dose-Response Relationship, Drug; Fasting; Female; Humans; Male; Middle Aged; Obesity; Overweight; Piperazines; Prospective Studies; Thiazoles; Waist Circumference; Weight Loss | 2011 |